Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

SIMPLE SUMMARY: Immune-checkpoint inhibitors (ICIs) are increasingly used in the treatment of cancer, but they cause immune-related adverse events (irAEs) in around 40% of patients treated. Identifying biomarkers predictive of irAEs has become a priority for the optimal management of patients on ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Les, Iñigo, Martínez, Mireia, Pérez-Francisco, Inés, Cabero, María, Teijeira, Lucía, Arrazubi, Virginia, Torrego, Nuria, Campillo-Calatayud, Ana, Elejalde, Iñaki, Kochan, Grazyna, Escors, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000735/
https://www.ncbi.nlm.nih.gov/pubmed/36900420
http://dx.doi.org/10.3390/cancers15051629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000735/
https://www.ncbi.nlm.nih.gov/pubmed/36900420
http://dx.doi.org/10.3390/cancers15051629

Ejemplares similares